Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-55573

Jacob, F; Meier, M; Caduff, R; Goldstein, D; Pochechueva, T; Hacker, N; Fink, D; Heinzelmann-Schwarz, V (2011). No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecologic Oncology, 121(3):487-491.

[img]Published Version
PDF - Registered users only
501kB

Abstract

OBJECTIVE: About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity for early cancers, many of which are potentially curable. METHODS: We compared the new commercially available tumor marker HE4 with CA125 individually, in combination, within the risk of malignancy index (RMI) and the newly defined risk of malignancy algorithm (ROMA). Our prospectively-collected cohort of 160 patients consisted of healthy controls, benign diseases, and borderline tumors/adenocarcinomas of ovarian, tubal, peritoneal and endometrial origin. HE4 and CA125 were measured in serum using standardized ELISA. RESULTS: Both markers showed similar diagnostic performance in the detection of EOC at clinically defined thresholds (CA125 35U/ml; HE4 70pM) but HE4 was not elevated in endometriosis. Comparison of non-malignant diagnoses (n=71) versus early stage ovarian and tubal cancers (n=19) revealed that HE4 and ROMA displayed the best diagnostic performance (AUC 0.86/0.87, specificity 85.9%/87.3% and sensitivity 78.9%/78.9%, respectively). Whilst RMICA125 detects peritoneal cancer better than all other models (AUC 0.99, specificity 97.2%, sensitivity 80.0%), there is no other detection benefit from RMI compared to HE4 alone or included in ROMA. CONCLUSIONS: The major advantage of HE4 lies in its specificity and improved detection of borderline tumors and early stage ovarian and tubal cancers. HE4 is superior to CA125 with or without RMI and ROMA indices. However, we see no benefit from combining both markers in clinical practice.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
DDC:610 Medicine & health
Language:English
Date:2011
Deposited On:21 Jan 2012 19:13
Last Modified:06 Dec 2013 08:25
Publisher:Elsevier
ISSN:0090-8258
Free access at:Related URL. An embargo period may apply.
Publisher DOI:10.1016/j.ygyno.2011.02.022
Related URLs:http://www.zora.uzh.ch/74343/
PubMed ID:21420727
Citations:Web of Science®. Times Cited: 42
Google Scholar™
Scopus®. Citation Count: 53

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page